Select display options below. (Cookies need to be enabled in your browser!)
Colors: High contrast    Default    Font Size: X-Large    Large    Medium    Default    Small   
Research & Clinical Trials

Study Detail: Ohr Squalamine Eye Drops for Wet AMD

Trial Description Summary
Participants are newly diagnosed, never treated wet macular degeneration in one eye who will intially be treated with one dose of Lucentis. They will then be randomly assigned to either squalamine eye drops twice a day or placebo eye drops twice a day. The need for subsequent injections of Lucentis will be evaluated monthly (weeks 4-32) and it retreatment criteria are met, Lucentis will be administered.

Basic Trial Information
Disease Status: newly diagnosed, never treated wet AMD
Age: 50 years or older 
Sponsor: Ohr Pharmaceutical
Protocol Number: Ohr-002
Status: anticipated enrollment Fall 2012
Study Duration: 9 months  

Inclusion Criteria
Greater than 50 years old. No upper limit.
Diagnosis of CNV secondary to AMD
     Total lesion area less than or equal to 12 disc areas 
     CNV affecting at least 50% of the total lesion area
     If hemorrhage must be 50% or less of the lesion- and no blood under the fovea
     No fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study eye or any              condition preventing VA improvement
     No pigment epithelial detachments without subretinal fluid or cystoid edema 
Central retinal thickness greater than or equal to 300 microns on Cirrus OCT
Presence of sub-retinal fluid or cystoid edema on OCT. 
VA 20/40 to 20/320 (25 to 70 letters ETDRS) 
If cataract extraction in the study eye, must be more than 3 months prior to enrollment as long as the    PC-IOL is in place.         

Exclusion Criteria
CNV secondary to any condition other than AMD in the study eye
Prior treatment in the study eye- CNV tx. allowed in fellow eye
Confounding ocular conditions such as diabetic retinopathy
VA worse that 20/200 (less than 34 letters) in the fellow eye
Prior ocular surgery in study eye (vitrectomy, scleral buckle
Glaucoma with the patient receiving treatment and having a VF defect or having had a filter/shunt
Cataract extraction less than 3 months prior to enrollment
Wearing of contact lenses

General Medical Exclusion
Myocardial infarction, cerebrovascular accident or transient ischemic attacks (TIA) within the past six months.
Currently on chemotherapy
Currently on systemic steroids
Investigational product use of any kind in the previous 30 days                                 

Other inclusion/exclusion criteria per protocol to be screened by the Clinical Coordinator

Study Title
Phase II study of the efficacy and safety of squalamine lactate in ophthalmic formulation 0.2% BID insubjects with neovascular AMD

Trial Contact Information
Study Coordinator: Vivian
Contact info: 216/831-5704 ext. 253